Key Insights

Highlights

Treatment Research

5 treatments under study, led by Spartalizumab

Research Leaders

5 sponsors active, led by Centre Hospitalier Regional Universitaire

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
Phase 2 (3)

Trial Status

Recruiting2
Unknown1

Clinical Trials (3)

Showing 3 of 3 trials
NCT04894370Phase 2RecruitingPrimary

Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma

NCT03944252Phase 2UnknownPrimary

Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS)

SYF022d5f36edd64062827d5373be62868ePhase 2Recruiting

Ezabenlimab (BI 754091) and DCFm (docetaxel, cisplatin and 5-fluorouracil) followed by chemoradiotherapy for the treatment of stage III anal canal cancer. Phase II study

Showing all 3 trials

Research Network

Common Treatments

  • Spartalizumab1
  • Ezabenlimab1
  • Avelumab1
  • Cetuximab1
  • Sample Collection1

Active Sponsors

  • Centre Hospitalier Regional Universitaire2
  • National Cancer Institute, France1
  • Centre Hospitalier Universitaire de Besancon1
  • Gruppo Oncologico del Nord-Ovest1
  • Novartis1

Related Conditions

  • Metastatic Squamous Cell Anal Carcinoma1
  • Metastatic Squamous Cell Carcinoma1

Activity Timeline